Market Place
Sourcing Support
Merck, Ridgeback withdraw COVID drug application in EU
27 Jun 2023 //
REUTERS
Merck and Ridgeback Provide Update on EU MAA for LAGEVRIO
24 Feb 2023 //
BUSINESSWIRE
NICE recommends against NHS use of 5 COVID treatments as not cost-effective
17 Nov 2022 //
REUTERS
Merck & Ridgeback Provide Update on Clinical & Non-Clinical Studies of LAGEVRIO
06 Oct 2022 //
BUSINESSWIRE
Emergent nets another manufacturing deal, for Ridgeback`s Ebola treatment
11 Jul 2022 //
ENDPTS
Merck and Ridgeback Announce New Data For LAGEVRIO From PIII MOVe-OUT Study
07 Jun 2022 //
BUSINESSWIRE
ICER`s latest cost analysis favors Paxlovid over molnupiravir
11 May 2022 //
FIERCEPHARMA
Merck sold $3.2B worth Molnupiravir, driving first-quarter revenue growth
29 Apr 2022 //
CNBC
Pfizer`s Paxlovid to be on tap for thousands more in the U.K.
13 Apr 2022 //
FIERCEPHARMA
Pfizer`s Paxlovid to be on tap for thousands more in the U.K.
12 Apr 2022 //
FIERCEPHARMA
Merck, Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO
01 Apr 2022 //
BUSINESSWIRE
Lessons learnt from the second wave: Tracking possibility of drug demand
22 Feb 2022 //
TRIBUNEINDIA
Merck’s Anti-Covid Pill Shows Better Effectiveness In Indian Study
19 Feb 2022 //
FORBES
Merck, Ridgeback Supplied 3.1M Courses of Molnupiravir to U.S. Government
08 Feb 2022 //
BUSINESSWIRE
Merck and Ridgeback’s Molnupiravir Demonstrated Activity Against Omicron Variant
28 Jan 2022 //
BUSINESSWIRE
Merck, Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir
18 Jan 2022 //
BUSINESSWIRE
Merck & Ridgeback’s Molnupiravir Nabs Special Approval for Emergency in Japan
24 Dec 2021 //
BUSINESSWIRE
UK government to purchase additional 1.75 million courses of Molnupiravir
23 Dec 2021 //
EXPRESSPHARMA
UK government to purchase additional 1.75 million courses of Molnupiravir
23 Dec 2021 //
EXPRESSPHARMA
Merck, Ridgeback Say U.K. Govt. to Buy Additional 1.75M Courses of Molnupiravir
22 Dec 2021 //
BUSINESSWIRE
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir
16 Dec 2021 //
BUSINESSWIRE
Merck, Ridgeback to Publish Phase 3 Study of Molnupiravir
16 Dec 2021 //
BUSINESSWIRE
Eagle Pharm`s Generic Vasopressin Receives Approval in the U.S.
15 Dec 2021 //
FDA
Ridgeback`s Biologic Ebanga (Ansuvimab) Receives Approval in the U.S.
07 Dec 2021 //
FDA
Merck ties up with Thermo Fisher to make its COVID-19 pill in Canada
07 Dec 2021 //
REUTERS
Why molnupiravir could still work for Merck
01 Dec 2021 //
EVALUATE
U.S. FDA panel to weigh Merck`s COVID-19 antiviral drug
30 Nov 2021 //
NPR
Merck & Ridgeback Report Full Phase 3 Analysis for Oral Antiviral COVID Pill
27 Nov 2021 //
TRIALSITENEWS
EMA receives MAA for Lagevrio for treating patients with COVID 19
24 Nov 2021 //
EMA
EMA CHMP issues advice on usage of Merck-Ridgeback’s Covid-19 medicine
22 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Merck Sells 1.6m Molnupiravir Courses to Japan
22 Nov 2021 //
TRIALSITESNEWS
EMA provides advice on using molnupiravir; to render decision on J&J’s booster
22 Nov 2021 //
RAPS
EU recommends Merck COVID-19 pill for adults at risk of severe illness
19 Nov 2021 //
REUTERS
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, at ASTMH
17 Nov 2021 //
BUSINESSWIRE
Buffett`s Berkshire exits Merck before COVID pill boost
17 Nov 2021 //
FIERCEPHARMA
Pfizer could net many more billions in COVID-19 pill sales
17 Nov 2021 //
FIERCEPHARMA
Deal with MPP will provide wide access for Pfizer`s COVID pills
16 Nov 2021 //
FIERCEPHARMA
Sun Pharma to introduce MSD & Ridgeback’s molnupiravir under brand name Molxvir
12 Nov 2021 //
PHARMABIZ
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million
10 Nov 2021 //
MERCK
Japan to pay $1.2 billion for 1.6 mln courses of Merck`s COVID-19 pill
10 Nov 2021 //
REUTERS
US to procure 1.4 million courses of molnupiravir for $1bn
09 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
U.S. to pay $1 billion for 1.4 million more courses of Merck`s COVID-19 pill
08 Nov 2021 //
INVESTING
EU to advise on Merck`s COVID-19 pill in "shortest possible" time
08 Nov 2021 //
REUTERS
Merck wins UK authorization to sell first COVID-19 pill
05 Nov 2021 //
BIOPHARMADIVE
Merck and Ridgeback`s COVID oral antiviral scores UK nod
05 Nov 2021 //
REUTERS
EMA starts rolling review of Merck`s COVID-19 antiviral
26 Oct 2021 //
REUTERS
Merck and Ridgeback Announce Initiation of a Rolling Review by the EMA
25 Oct 2021 //
BUSINESSWIRE
Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak
20 Oct 2021 //
BUSINESSWIRE
Atea and Roche`s COVID-19 antiviral flunks phase 2
20 Oct 2021 //
FIERCEBIOTECH
WHO campaign seeks to buy COVID-19 antivirals for $10
20 Oct 2021 //
FIERCEPHARMA
Merck seeks FDA nod for COVID antiviral 10 days after data drop
12 Oct 2021 //
REUTERS
Merck, Ridgeback seek US clearance of first oral COVID-19 drug
11 Oct 2021 //
BIOPHARMADIVE
Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19
09 Oct 2021 //
REUTERS
3 countries sign deals for Merck`s molnupiravir, others in talks
07 Oct 2021 //
FIERCEPHARMA
Merck`s antiviral for COVID won`t affect vaccines in short term
06 Oct 2021 //
FIERCEPHARMA
India`s Divi`s Labs hits record high on Merck`s +ve trial data for COVID-19 drug
04 Oct 2021 //
REUTERS
India`s Divi`s Labs hits record high on Merck`s +ve trial data for COVID-19 drug
04 Oct 2021 //
REUTERS
Merck, Ridgeback announce positive results from phase 3 study of molnupiravir
04 Oct 2021 //
PHARMABIZ
Merck`s Covid-19 pill is great news but may not be a game-changer
02 Oct 2021 //
ECONOMICTIMES
Unexpected win opens the way to an oral Covid antiviral
01 Oct 2021 //
EVALUATE
